A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 15 references indexed in Scilit:
- SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020–2023Nature Communications, 2024
- Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational studyThe Lancet Infectious Diseases, 2024
- Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection studyThe Lancet Microbe, 2024
- Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and Trends from the Ongoing EPOCH-US StudyAdvances in Therapy, 2024
- Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressureThe Lancet Infectious Diseases, 2023
- Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron eraExpert Review of Vaccines, 2023
- Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year OldsJournal of the Pediatric Infectious Diseases Society, 2023
- Effect of covid-19 vaccination on long covid: systematic reviewBMJ Medicine, 2023
- Epidemiology and Clinical Presentation of COVID-19 in Older AdultsInfectious Disease Clinics of North America, 2022
- Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variantHuman Vaccines & Immunotherapeutics, 2022